Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.

J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit

Abbott Labs

Atmos Energy

Cardinal Health

Colgate-Palmolive

Con Ed

Coca-Cola

J. M. Smucker

We follow the bond market closely at 24/7 Wall St., and for almost a year now there has been an inversion (or difference in yield) between the two-year Treasury paper and the benchmark 10-year note.

8 Dividend Aristocrat Stocks to Buy Now With a Recession (and Inflation) Looming Large in 2024

Johnson & Johnson said on Wednesday it has decided to stop a late-stage study testing its experimental drug to treat a type of hypertension.

J&J to pull the plug on hypertension drug study

IBM said on Wednesday it is notifying customers of Janssen CarePath, a Johnson & Johnson unit, of a "data incident" involving unauthorized access of personal information.

IBM notifies J&J unit Janssen CarePath's customers of unauthorized data access

Cidara Therapeutics

Shares of Cidara Therapeutics soared 18.5% in early New York trading, buoyed by news that Janssen Pharmaceuticals, a subsidiary of healthcare giant Johnson & Johnson (NYSE:JNJ) Inc, is set to champion the development of Cidara's promising flu prevention drug, CD388. Preliminary tests have already highlighted the treatment's potential: a single dose notably reduced flu symptoms and was found to be safe for users.

Cidara shares surge 18.5% as J&J unit Janssen takes lead on flu drug

Johnson & Johnson said on Wednesday its combination drug helped increase the duration of no progress in a type of non small-cell lung cancer in patients.

J&J says drug combo contains lung cancer from spreading for longer duration

Apple

Alphabet

Microsoft

PepsiCo

Procter & Gamble

Here's a look at the top long-term retirement stocks to buy now. Building a solid retirement portfolio is all about identifying companies that can withstand any storm in the market.

7 Retirement Stocks That Every Long-Term Investor Should Own Now

J&J recently completed the spinoff of its consumer health business, letting go of star products that populate most of our medicine cabinets. But J&J's two other units, pharmaceuticals and medtech, actually have driven more growth for the company in recent times.

Is J&J a Buy After the Kenvue Separation?

Walgreens

Many view the 30 stocks that comprise the Dow Jones Industrial Average as safe, solid “blue-chip” stocks that will never drop a great deal. For example, the business news company Kiplinger wrote: “The Dow Jones Industrial Average comprises 30 blue-chip stocks that are tops in their industries.

3 Dow Stocks to Sell in September Before They Crash and Burn

The healthcare giant's separation of its consumer-health business arms it with billions in cash for allocating capital in the remaining businesses.

J&J's $40 Billion Split-Off Sets Stage for Pharma, Medical Tech Expansion ﻿

Mastercard

Visa

Johnson & Johnson is a long-time healthcare leader with 61 straight years of dividend hikes. Visa and Mastercard have very little competition in their industry, and both still have growth potential.

4 Warren Buffett Stocks That Could Join the Trillion-Dollar Club by 2032

Johnson & Johnson refreshed its financial guidance following its split from Kenvue. The healthcare behemoth offset most of the financial impact of the split because the exchange offer lowered its share count.

Is This Incredible Dividend Stock Still a Buy Following Its Recent Split?

AstraZeneca

Bristol-Myers

Eli Lilly

Merck

Pfizer

The Medicare Modernization Act that established the Part D program in 2003 prohibited the federal government from negotiating drug prices with manufacturers. The Inflation Reduction Act, signed into law by President Biden last year, allows Medicare to start negotiating the prices it will pay for some widely used drugs.

8 Pharma Stocks Affected by New Drug Price Negotiation Rules

Moderna

Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.

Judge withdraws from Medicare drug price case after stock ownership is revealed

Aflac

Coca-Cola Femsa SAB de CV

Realty Income Corp

Verizon

Waste Management

The rally we've seen in previous weeks has given investors a breath of fresh air, but I believe volatility is likely to persist over the next few months. With the Federal Reserve committed to further rate hikes, turbulence could easily return to the markets later this year.

7 Cash Cow Stocks for Recession-Resilient Dividends

Johnson & Johnson stock (NYSE: JNJ) has seen a 3% fall in a month, compared to a 2% fall for the broader S&P500 index.

What's Happening With Johnson & Johnson Stock?

Astellas Pharma Inc

Amgen

Horizon Pharma

Novo Nordisk

Novartis

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.

J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation

Danaher

Artificial Intelligence ( AI ) has received incredible attention this year due to the public release of OpenAI's  ChatGPT. Its profound capabilities have successfully captured the imaginations of a swath of audiences from technology enthusiasts and investors to social commentators.

When ChatGPT Misses the Mark: 3 Stocks It Got Very Wrong

Johnson & Johnson is cutting its drug development efforts for infectious diseases. It hasn't said anything about ceasing sales of its products on the market.

Johnson & Johnson Just Cut an Entire Division. Is It Still a Buy?

3M and Johnson & Johnson have been increasing their dividend payments for decades. They offer above-average dividend yields, with 3M paying as much as 6%.

2 Dividend Kings That Face Massive Legal Risks

Three of Johnson & Johnson's blockbusters are on Medicare's price negotiation list. Drugmakers have filed court cases fighting the government's plan to directly negotiate prices.

Medicare Will Soon Negotiate Some Drug Prices. Is This a Threat to Johnson & Johnson's Earnings?

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

News for Johnson & Johnson Stock (JNJ)